Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial
- PMID: 20693186
- PMCID: PMC3111931
- DOI: 10.1177/1740774510381285
Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial
Abstract
Background: The Clarification of Optimal Anticoagulation through Genetics (COAG) trial is a large, multicenter, double-blinded, randomized trial to determine whether use of a genotype-guided dosing algorithm (using clinical and genetic information) to initiate warfarin treatment will improve anticoagulation status when compared to a dosing algorithm using only clinical information.
Purpose: This article describes prospective alpha allocation and balanced alpha allocation for the design of the COAG trial.
Methods: The trial involves two possibly heterogeneous populations, which can be distinguished by the difference in warfarin dose as predicted by the two algorithms. A statistical approach is detailed, which allows an overall comparison as well as a comparison of the primary endpoint in the subgroup for which sufficiently different doses are predicted by the two algorithms. Methods of allocating alpha for these analyses are given - a prospective alpha allocation and allocating alpha so that the two analyses have equal power, which we call a 'balanced alpha allocation.'
Results: We show how to include an analysis of the primary endpoint in a subgroup as a co-primary analysis. Power can be improved by incorporating the correlation between the overall and subgroup analyses in a prospective alpha allocation approach. Balanced alpha allocation for the full cohort and subgroup tests to achieve the same desired power for both of the primary analyses is discussed in detail.
Limitations: In the COAG trial, it is impractical to stratify the randomization on subgroup membership because genetic information may not be available at the time of randomization. If imbalances in the treatment arms in the subgroup are found, they will need to be addressed.
Conclusions: The design of the COAG trial assures that the subgroup in which the largest treatment difference is expected is elevated to a co-primary analysis. Incorporating the correlation between the full cohort and the subgroup analyses provides an improvement in power for the subgroup comparison, and further improvement may be achieved via a balanced alpha allocation approach when the parameters involved in the sample size calculation are reasonably well estimated.
Similar articles
-
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.Trials. 2010 Nov 17;11:108. doi: 10.1186/1745-6215-11-108. Trials. 2010. PMID: 21083927 Free PMC article. Clinical Trial.
-
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.Am Heart J. 2013 Sep;166(3):435-41. doi: 10.1016/j.ahj.2013.04.009. Epub 2013 Jul 12. Am Heart J. 2013. PMID: 24016491 Free PMC article. Clinical Trial.
-
A systematic analysis and comparison of warfarin initiation strategies.Pharmacogenet Genomics. 2016 Oct;26(10):445-52. doi: 10.1097/FPC.0000000000000235. Pharmacogenet Genomics. 2016. PMID: 27383664 Free PMC article.
-
Warfarin pharmacogenomics: current best evidence.J Thromb Haemost. 2015 Jun;13 Suppl 1:S266-71. doi: 10.1111/jth.12978. J Thromb Haemost. 2015. PMID: 26149035 Review.
-
Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.J Cardiovasc Pharmacol. 2019 Mar;73(3):127-135. doi: 10.1097/FJC.0000000000000656. J Cardiovasc Pharmacol. 2019. PMID: 30688796
Cited by
-
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial.Trials. 2010 Nov 17;11:108. doi: 10.1186/1745-6215-11-108. Trials. 2010. PMID: 21083927 Free PMC article. Clinical Trial.
-
Personalized medicine: is it a pharmacogenetic mirage?Br J Clin Pharmacol. 2012 Oct;74(4):698-721. doi: 10.1111/j.1365-2125.2012.04328.x. Br J Clin Pharmacol. 2012. PMID: 22591598 Free PMC article. Review.
-
Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial.JAMA. 2017 Sep 26;318(12):1115-1124. doi: 10.1001/jama.2017.11469. JAMA. 2017. PMID: 28973620 Free PMC article. Clinical Trial.
-
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.Am Heart J. 2013 Sep;166(3):435-41. doi: 10.1016/j.ahj.2013.04.009. Epub 2013 Jul 12. Am Heart J. 2013. PMID: 24016491 Free PMC article. Clinical Trial.
-
A systematic analysis and comparison of warfarin initiation strategies.Pharmacogenet Genomics. 2016 Oct;26(10):445-52. doi: 10.1097/FPC.0000000000000235. Pharmacogenet Genomics. 2016. PMID: 27383664 Free PMC article.
References
-
- Ansell JE. Oral anticoagulant therapy – 50 years later. Arch Intern Med. 1993;153:586–96. - PubMed
-
- Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690–98. - PubMed
-
- Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:3385–93. - PubMed
-
- Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329–33. - PubMed
-
- Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563–70. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous